GILEAD SCIENCES, INC. Available-for-sale Securities, Equity Securities
GILEAD SCIENCES, INC. (GILD) had Available-for-sale Securities, Equity Securities of $280.00 million as of 2016-03-31, per its 10-Q filed 2016-05-06.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesEquitySecurities · last filed 2016-05-06
- 2016-03-31: Available-for-sale Securities, Equity Securities $280.00M.
- 2012-12-31: Available-for-sale Securities, Equity Securities $0.00.
- 2012-09-30: Available-for-sale Securities, Equity Securities $0.00.
- 2012-06-30: Available-for-sale Securities, Equity Securities $0.00.
| Period end | Available-for-sale Securities, Equity Securities |
|---|---|
| 2016-03-31 | $280.00M 10-Q · filed 2016-05-06 |
| 2012-12-31 | $0.00 10-K · filed 2013-02-27 |
| 2012-09-30 | $0.00 10-Q · filed 2012-11-06 |
| 2012-06-30 | $0.00 10-Q · filed 2012-08-01 |
| 2012-03-31 | $0.00 10-Q · filed 2012-05-04 |
| 2011-12-31 | $8.50M 10-K · filed 2013-02-27 |
| 2011-09-30 | $5.27M 10-Q · filed 2011-11-04 |
| 2011-06-30 | $8.30M 10-Q · filed 2011-08-05 |
| 2011-03-31 | $7.98M 10-Q · filed 2011-05-09 |
| 2010-12-31 | $4.63M 10-K · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |